Pharmaceutical Technology

FEBRUARY 13, 2023

SOPHiA GENETICS is expanding its collaboration with AstraZeneca to include multimodal approaches for developing cancer drugs. This collaboration aims to use the global SOPHiA DDM platform, a cloud-native platform of SOPHiA GENETICS, and multimodal algorithmic capabilities for AstraZeneca’s oncology portfolio.

Genetics 130

Genetics Development Drugs Genome 130

XTalks

MAY 23, 2024

One of the more intriguing developments in cancer research in recent years is the growing understanding of clonal hematopoiesis, a phenomenon where blood cells expand from a single clone due to genetic mutations. Clonal hematopoiesis increases in prevalence with age and can precede hematologic malignancies.

Genetics 114

Genetics Research Genome Genomics 114

pharmaphorum

JANUARY 18, 2023

In 2016, scientists behind a study called the Resilience Project analysed genetic data from 589,000+ people and found 13 adults who carried genetic variants that should have resulted in serious – even deadly – childhood disease, but who were apparently healthy. Giving participants something in return.

Genetic Disease 95

Genetic Disease Genetics Research Genome 95

Drug Discovery World

NOVEMBER 7, 2022

A new study led by Medical Research Council-funded researchers from UCL has found that tailoring the analysis of whole genome sequencing to individual patients could double the diagnostic rates of rare diseases. . Consequently, the UK has established itself at the forefront of diagnostic whole genome sequencing. Context .

Genome 52

Genome Genomics Genetics Genetic Disease 52

pharmaphorum

MARCH 24, 2022

There’s a rich history of finding useful medicines from fungi, from the antibiotic penicillin to immune suppressant cyclosporine and cholesterol drug lovastatin. The post GSK partners LifeMine on fungi-derived medicines appeared first on. Greg Verdine – LifeMine. Image by jggrz from Pixabay .

Medicine 104

Medicine Genome Genomics Engineer 104

Drug Discovery World

JUNE 21, 2023

The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Exact Sciences, Guardant Health, Illumina, MSD and Novartis have come together to launch the European Coalition for Access to Comprehensive Genomic Profiling (ECGP).

Genome 52

Genome Genomics Medicine Clinical Trials 52

Cloudbyz

JULY 31, 2024

The landscape of modern medicine is rapidly evolving, driven by groundbreaking advancements in diagnostics. This revolution is enabling the growth of innovative biomarker-based precision medicine and cell and gene therapy, transforming both clinical research and post-market care.

Gene Therapy 52

Gene Therapy Gene Medicine In-Vitro 52

Roots Analysis

JANUARY 22, 2024

However, these approaches are incompetent for dealing with intrinsic carcinogenic genetic abnormalities. This resulted in the discovery of an individualized concept of treatment known as oncology precision medicine which primarily utilizes the patient’s genomic information to provide gene-targeted diagnostics and therapeutics.

Medicine 40

Medicine Genetics Genome Genomics 40

XTalks

NOVEMBER 7, 2022

These tumor-derived entities are used to derive genomic and proteomic data. Gleich, MD, FACS, Senior Vice President, Medical Department, and Dr. Christopher Huth, PhD, Senior Clinical Trial Manager, Clinical Trial Management. Liquid Biopsy Use in Oncology Clinical Trials.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Drug Discovery World

AUGUST 16, 2023

A new study has shed light on the genetic messages encoded by genes within ‘triple negative’ breast cancers (TNBC), and shows they could predict response to chemotherapy. The presence of these biomarkers could be used to accelerate the development of more personalised treatments for triple negative breast cancers.

Genetics 52

Genetics Gene Hormones RNA 52

Drug Discovery World

FEBRUARY 12, 2024

Dr Pandora Pound , Fellow Oxford Centre for Animal Ethics explores the hinderances of animal testing in pharma and why new technologies such AI, genomics and synthetic biology c an further drug development. Why has there been so little progress in medicine? Why has it been so unproductive?

Medicine 59

Medicine Genome Genomics Drugs 59

XTalks

DECEMBER 1, 2020

Over the past several years, personalized medicine has led the charge in medical innovation, leading drug development efforts as well as furthering the research community’s understanding of human disease states. With this has come an increase in the size of the global clinical trials market, with an estimated worth of around $46.8

Clinical Trials 96

Clinical Trials Clinical Trials Trials Clinical Research 96

ACRP blog

JUNE 7, 2023

At the same time, thought leaders in the field are endeavoring to ensure that real people—the ultimate beneficiaries of these rapidly evolving capabilities for clinical trial design and management—are not getting lost in the shuffle. Undoubtedly, the expectations for precision medicine are high,” Olsen adds.

Big Data 59

Big Data Clinical Research Research Clinical Trials 59

Cloudbyz

JUNE 26, 2023

This can aid in personalized medicine, disease management, and risk assessment, leading to improved patient care and outcomes. Clinical Trial Design and Optimization: Generative AI can aid in the design and optimization of clinical trials.

Clinical Research 97

Clinical Research Research Clinical Trials Clinical Trials 97

Pharmaceutical Technology

JULY 5, 2022

Researchers at the UNC School of Medicine have discovered that hepatitis A virus (HAV) replication needs particular interactions between the human protein ZCCHC14 and TENT4 poly(A) polymerases, a group of enzymes. HAV usually hijacks TENT4 and utilises it for the replication of its own genome.

Protein 130

Protein RNA Genome Genomics 130

pharmaphorum

SEPTEMBER 16, 2022

Essentially, the collaboration brought together both “the right expertise and the right technology”, opening up myriad possibilities for targeting GPCRs within the human genome. Kim recognised then, he said, that better tools for medicine needed to be developed, and that they still do. But mere volition does not enact results.

Development 135

Development Research Drugs Clinical Trials 135

Scienmag

OCTOBER 28, 2020

The COVID-19 Host Genetics Initiative was created to study the relationship between variation in the human genome and SARS-CoV-2 infection. Insights into why some people develop more severe symptoms than others and how to better treat the disease are desperately needed. This is an […].

Genetics 40

Genetics Genome Genomics Development 40

pharmaphorum

OCTOBER 18, 2022

US-based Tempus has built a precision medicine platform – powered by artificial intelligence and machine learning – that sifts through a large library of anonymised patient data, including results of clinical, molecular, and genomic testing. The two companies have been working together for some time.

Production 52

Production Clinical Trials Clinical Trials Genome 52

Drug Discovery World

DECEMBER 5, 2022

AI-driven genomics company Genomenon will partner with COMBINEDBrain, SynGAP Research Fund, and SLC-6A1 Connect and their pharma partners to deliver genomic data on their diseases of focus. . This lack of comprehensive data increases the risk of program failure in clinical trials. .

Development 52

Development Genome Genomics Drugs 52

XTalks

JULY 24, 2024

They also address diversity in clinical trials by supporting efforts to improve the representation of underrepresented patient populations. AI-driven models also help in identifying the most effective treatment regimens based on patient-specific factors, including genetic makeup and treatment history. Nanostics Inc.

Big Data 52

Big Data Clinical Trials Clinical Trials Life Science 52

Drug Discovery World

NOVEMBER 14, 2023

FH is one of the most common genetic conditions, affecting around one in 300 people globally. Since the mutation only affects a single gene, it makes it a prime candidate for genome editing treatments. It is caused by a single gene mutation that impairs the body’s ability to mediate LDL cholesterol.

In-Vivo 52

In-Vivo Gene Editing Gene Genome 52

XTalks

JUNE 18, 2024

In a field quickly gaining attention for its role in vaccine development and personalized medicine, Elixirgen Therapeutics stands out through its pursuit of innovation and safety. Founded in Baltimore, Maryland, a vibrant science hub, Elixirgen Therapeutics emerged from a vision to harness the untapped potential of mRNA technology.

Protein 52

Protein RNA Genetics Clinical Trials 52

Drug Discovery World

DECEMBER 6, 2023

The investment will fuel pre-IND and IND activities to achieve early human data readouts in a PhIb/IIa clinical trial. We feel this reflects the strong support for our vision and confirms the potential of Eligo to create a novel class of transformative genetic medicines.”

Gene Editing 52

Gene Editing Gene In-Vivo Genetics 52

XTalks

DECEMBER 20, 2023

This includes analyzing how drug combinations may impact individual patients or groups of patients before even entering a clinical trial. With a staggering 90 percent of drugs failing in clinical trials, AI has the potential to help improve these statistics.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

The Pharma Data

SEPTEMBER 28, 2020

Insights from project could potentially improve precision medicine use for paediatric AML. Accenture Applied Intelligence announced a new data and analytics approach to manage and derive insights from paediatric acute myeloid leukaemia (AML) genomic data, with the potential to improve precision medicine.

Genome 52

Genome Genomics Clinical Trials Clinical Trials 52

Drug Discovery World

MAY 17, 2024

Deepika Khedekar , Associate Centralized Clinical Trial Lead at IQVIA Inc, looks at the challenges of utilising artificial intelligence (AI) in oncology clinical research. MIT research 4 tells us a hard truth: about 95% of these trials fall short, leaving behind a trail of broken hopes for cancer patients each year.

Trials 59

Trials Clinical Trials Clinical Trials Protein 59

pharmaphorum

JANUARY 29, 2021

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, which are proteins that can be used to edit genomes by knocking select genes in or out to specifically modify DNA sequences.

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

Drug Discovery World

AUGUST 10, 2023

Reece Armstrong speaks to Neil Dhawan , the Co-founder and CEO of Totus Medicines about the company’s approach to drug discovery using fundamental technologies in chemistry, biology and artificial intelligence (AI). RA: How is Totus Medicines attempting to target untreatable or undruggable diseases? How can this impact drug discovery?

Genome 52

Genome Genomics Genetics Medicine 52

Drug Discovery World

APRIL 18, 2023

Exome sequencing correctly identified individuals with cancer predisposition syndromes who would have been missed by current screening guidelines, according to results from the Tapestry clinical trial. would not have qualified for genetic screening under current guidelines. Of these individuals, 52.1%

Genetics 52

Genetics Gene Medicine Clinical Trials 52

pharmaphorum

JULY 20, 2022

Armed with a $100 million second-round financing, CAMP4 Therapeutics is preparing to start the first clinical trial of a drug targeting regulatory RNA (regRNA) molecules that can be used to fine-tune the expression of genes. ” The post CAMP4 raises $100m to take lead RNA drugs into clinic appeared first on. .

RNA 52

RNA Genetic Disease Drugs Protein 52

Bioengineer

JULY 22, 2021

Geneticists from Trinity College Dublin have discovered how a specific genetic mutation called H3K27M causes a devastating, incurable childhood cancer, known as diffuse midline glioma (DMG), and – in lab studies working with model cell types – successfully reverse its effects to slow cancer cell growth with a targeted drug.

Genetics 52

Genetics Drugs Clinical Trials Clinical Trials 52

XTalks

FEBRUARY 27, 2024

There have been significant advancements in new rare disease drugs, particularly for genetic disorders that can be treated by correcting, replacing or silencing defective genes. These approaches help ensure that trials address the needs and concerns of the rare disease community. The FDA introduced its Orphan Drug Act in 1983.

Research 59

Research Drugs Gene Therapy Clinical Trials 59

Drug Discovery World

FEBRUARY 6, 2024

As AI-designed drugs start to enter large-scale clinical trials, DDW’s Diana Spencer investigates how new digital tools are reinventing and reshaping drug discovery for the future. Relation Therapeutics, which uses high-resolution biology, ML and clinical insights to discover transformational medicines.

Marketing 69

Marketing Medicine Genome Genomics 69

XTalks

APRIL 24, 2023

Approximately 72 percent of rare diseases are genetic, and around 70 percent of rare genetic diseases emerge in childhood. The webinar included operational strategies for these trials from Laura Omoboni, MS, Executive Director of Clinical Trial Management. Rare diseases can often be progressive, chronic and fatal.

Gene Therapy 95

Gene Therapy Gene Trials Clinical Trials 95

Drug Discovery World

DECEMBER 15, 2022

Vor Bio, a clinical-stage cell and genome engineering company, has announced initial clinical data from VBP101, its Phase I/IIa multicentre, open-label, first-in-human study of tremtelectogene empogeditemcel or “trem-cel” (formerly VOR33) in patients with acute myeloid leukemia (AML). . A product dose of 7.6

Drugs 52

Drugs Genome Genomics Engineer 52

pharmaphorum

SEPTEMBER 14, 2020

Last week geneticist Dr Charles Steward shared with us his experiences of searching for a genetic cause for his children’s rare neurological diseases. Here he gives us a deeper look at how genomic medicine is evolving and the barriers that are preventing it from reaching its full potential.

Genome 119

Genome Genomics Medicine Gene 119

pharmaphorum

SEPTEMBER 12, 2022

Alongside drugs and therapeutics, data collection and technology enhancements have redefined the traditional healthcare experience, especially within oncology, and genomic profiling has become a significant factor in allowing for personalised care. In other words, every person’s cancer has its own genetic construct. Tailored oncology.

Genome 105

Genome Genomics Clinical Trials Clinical Trials 105